Top Research Reports for Exxon Mobil, Merck & Qualcomm

About this update from Fomento Economico Mexicano Sab De Cv Units Cons. Of 5 Shsb

Friday, July 12, 2024The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Exxon Mobil Corp. (XOM), Merck & Co., Inc. (MRK) and Qualcomm Inc. (QCOM), as well as a micro-cap stock Armanino Foods of Distinction, Inc. (AMNF). The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.You can see all of today’s research reports here >>>Exxon Mobil’s shares have outperformed the Zacks Oil and Gas - Integrated - International industry over the past year (+8.0% vs. +5.3%). The company is a reliable player in the energy sector, boasts a resilient capital structure, a robust balance sheet and track record of prudent capex management. Its strategic discoveries in the Stabroek Block and Permian Basin promise growth and lower greenhouse gas intensity. Exxon Mobil prioritizes shareholder returns, evidenced by substantial buybacks that are slated to increase to $20 billion through 2025. Exxon Mobil’s entry into the lithium market positions it for long-term gains as the demand for lithium is poised to increase with the growing adoption of electric vehicles.However, challenges loom, notably in the upstream operations, which are susceptible to volatile oil prices and regulatory hurdles. Reliance on finding economically recoverable reserves and exposure to OPEC production cuts add to uncertainties.(You can read the full research report on Exxon Mobil here >>>)Shares of Merck’s have gained +21.2% over the past year against the Zacks Large Cap Pharmaceuticals industry’s gain of +35.1%. The company’s products like Keytruda and Gardasil have been driving sales. With continued label expansion into new indications, particularly earlier-stage launches, Keytruda is expected to see continued growth. Animal health and vaccine products are core growth drivers. Merck boasts a strong cancer pipeline, including Keytruda, which should drive long-term growth. The company is investing in M&A activity to strengthen its pipeline. However, generic competition for several drugs and rising competitive pressure, mainly on the diabetes franchise, will continue to be overhangs on the top l...

View stock analysis, news, and events for Fomento Economico Mexicano Sab De Cv Units Cons. Of 5 Shsb